Breast Cancer Clinical Trial
Official title:
A Phase I/II Pilot Study of Patients With Brain Metastasis Secondary to Breast Cancer Treated With Methotrexate and Carboplatin in Conjunction With Blood-Brain Barrier Disruption, With Concurrent Trastuzumab in HER-2 Positive Patients
Verified date | April 2017 |
Source | OHSU Knight Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Osmotic blood-brain barrier disruption uses certain drugs, such as mannitol, to
open the blood vessels around the brain and allow tumor-killing substances to be carried
directly to the brain. Drugs used in chemotherapy, such as methotrexate and carboplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Trastuzumab
may also help methotrexate and carboplatin work better by making tumor cells more sensitive
to the drugs. Giving osmotic blood-brain barrier disruption together with methotrexate,
carboplatin, and trastuzumab may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin
when given together with methotrexate and trastuzumab after mannitol in treating women with
breast cancer that has spread to the brain.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | October 2013 |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed breast cancer metastatic to the central nervous system (as documented by brain biopsy, cytology [analysis from cerebrospinal fluid]) OR radiographic evidence of brain metastasis with a diagnosis of systemic breast cancer - Patients must have stable or no systemic disease as determined by a CT scan of the chest, abdomen, and pelvis - HER2-positive or -negative disease by fluorescent in situ hybridization (FISH) or immunohistochemistry - Patients with HER2-positive disease and signs of intracranial herniation and/or spinal block may first undergo intraarterial chemotherapy off study (with carboplatin, methotrexate, and trastuzumab [Herceptin®] by the same routes used on study) until radiographically shown to be safe to undergo blood brain barrier disruption, at which point they may be enrolled in the study - Hormone receptor status not specified PATIENT CHARACTERISTICS: - Female - Menopausal status not specified - ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% - Life expectancy > 6 weeks - Hematocrit = 25% - WBC = 2,500/mm³ - Absolute neutrophil count = 1,200/mm³ - Platelet count =100,000/mm³ - Creatinine clearance = 50 mL/min (eligible for full-dose methotrexate) (30-49 mL/min allowed for patients receiving reduced-dose methotrexate) - Bilirubin = 2.0 times upper limit of normal - LVEF normal by echocardiogram or MUGA - Adequate pulmonary and cardiac function to tolerate general anesthesia as determined by physical examination and history - No New York Heart Association class III-IV heart disease - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No known allergy to trastuzumab (HER2-positive patients), carboplatin, methotrexate, or sodium thiosulfate - No hepatitis B or C positivity - No uncontrolled intercurrent illness including, but not limited to, any of the following: - Ongoing or active infection (e.g., HIV) - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia - Psychiatric illness or social situations that would limit compliance with study requirements PRIOR CONCURRENT THERAPY: - Prior surgery or biopsy allowed - Prior chemotherapy and radiation therapy for metastatic breast cancer allowed - No radiation or cytotoxic chemotherapy within the past 4 weeks (except trastuzumab or hormone therapy that has been part of the patient's ongoing treatment [e.g., aromatase inhibitors for estrogen receptor positive patients]) - No noncytotoxic regimens (e.g., targeted oral agents) within the past 2 weeks - No investigational agents within the past 4 weeks - No other concurrent anticancer agents or therapies |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
OHSU Knight Cancer Institute | National Cancer Institute (NCI) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival exceeding 5 months in patients with Human Epidermal growth factor Receptor 2(HER2)-negative disease | 1 year after initiation of treatment | ||
Primary | Overall survival exceeding 5 months in patients with HER2-positive disease | 1 year after initiation of treatment | ||
Secondary | Overall survival | 5 years after intitiation of treatment | ||
Secondary | Progression-free survival | 5 years | ||
Secondary | Complete response rate | 5 years | ||
Secondary | Time to best response | 5 years | ||
Secondary | Quality of life | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |